SOURCE: Basilea Pharmaceutica AG

September 28, 2007 13:08 ET

Basilea Announces Submission of Marketing Authorization Application for Alitretinoin to Swiss Regulatory Authority

BASEL, SWITZERLAND--(Marketwire - September 28, 2007) - Basilea Pharmaceutica Ltd. (SWX: BSLN) announced today the submission of a marketing authorization application to Swissmedic for its investigational drug alitretinoin. The submission supports the proposed use of oral alitretinoin in severe refractory chronic hand eczema. Basilea also announced the appointment of Mr. Hans Christian Rohde as Global Head of Commercial Operations.

The marketing authorization application seeks approval for oral alitretinoin in the treatment of severe refractory chronic hand eczema (CHE) and is based on a clinical program comprising almost 2000 patients.

Recently, marketing authorization applications for alitretinoin in severe refractory CHE have been submitted to various EU member states.

Basilea Pharmaceutica Ltd. also announced today the appointment of Mr. Hans Christian Rohde as Global Head of Commercial Operations. This new appointment will further expand Basilea's capabilities to support its product launches and future company growth.

Mr. Rohde has held senior positions in international marketing, sales and general management with Novo Nordisk, Biogen and Serono both in Europe and the United States. He was most recently a Global Therapeutic Area Head, Corporate Marketing at Merck Serono. He was responsible for numerous successful global product launches during his 19 year career in the pharmaceutical industry. Mr. Rohde will join Basilea's Management team shortly. Basilea announces that Mr. Nicholas Benedict, Head of Commercial Operations, has decided to leave the company for personal reasons. Mr. Benedict made a significant contribution to setting up Basilea's commercial infrastructure to prepare for the imminent product launches and Basilea wishes him much success for the future.

About Chronic Hand Eczema

Hand eczema is a common skin disease and is often chronic and relapsing. It is estimated to affect up to 10% of the general population. The more severe, chronic form of the condition is thought to affect up to 7% of these patients, many of whom do not respond, or no longer respond to topical corticosteroids. Basilea estimates there are at least five hundred thousand patients in Europe with refractory severe CHE.

About Basilea

Basilea Pharmaceutica Ltd. is an integrated biopharmaceutical company headquartered in Basel, Switzerland, listed on the SWX Swiss Exchange (SWX: BSLN). Basilea is currently focused on the research, development and commercialization of new antibacterial, antifungal and dermatology drugs in the hospital and specialty care setting.


This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

This press release can be downloaded from

Copyright © Hugin ASA 2007. All rights reserved.

Contact Information